1
|
Kunimoto H, Miura A, Maeda A, Tsuchida N, Uchiyama Y, Kunishita Y, Nakajima Y, Takase-Minegishi K, Yoshimi R, Miyazaki T, Hagihara M, Yamazaki E, Kirino Y, Matsumoto N, Nakajima H. Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome. Int J Hematol 2023; 118:494-502. [PMID: 37062784 DOI: 10.1007/s12185-023-03598-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Revised: 04/03/2023] [Accepted: 04/03/2023] [Indexed: 04/18/2023]
Abstract
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a new disease entity with autoinflammatory disorders (AID) driven by somatic variants in UBA1 that frequently co-exists with myelodysplastic syndromes (MDS). Clinicopathological and molecular features of Japanese cases with VEXAS-associated MDS remain elusive. We previously reported high prevalence of UBA1 variants in Japanese patients with relapsing polychondritis, in which 5 cases co-occurred with MDS. Here, we report clinicopathological and variant profiles of these 5 cases and 2 additional cases of MDS associated with VEXAS syndrome. Clinical characteristics of these cases included high prevalence of macrocytic anemia with marked cytoplasmic vacuoles in myeloid/erythroid precursors and low bone marrow (BM) blast percentages. All cases were classified as low or very low risk by the revised international prognostic scoring system (IPSS-R). Notably, 4 out of 7 cases showed significant improvement of anemia by treatment with prednisolone (PSL) or cyclosporin A (CsA), suggesting that an underlying inflammatory milieu induced by VEXAS syndrome may aggravate macrocytic anemia in VEXAS-associated MDS. Targeted deep sequencing of blood samples suggested that MDS associated with VEXAS syndrome tends to involve a smaller number of genes and lower risk genetic lesions than classical MDS.
Collapse
Affiliation(s)
- Hiroyoshi Kunimoto
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Ayaka Miura
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Ayaka Maeda
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Naomi Tsuchida
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
- Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
- Department of Rare Disease Genomics, Yokohama City University Hospital, Yokohama, Japan
| | - Yuri Uchiyama
- Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
- Department of Rare Disease Genomics, Yokohama City University Hospital, Yokohama, Japan
| | - Yosuke Kunishita
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Yuki Nakajima
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Kaoru Takase-Minegishi
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Ryusuke Yoshimi
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Takuya Miyazaki
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Maki Hagihara
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Yohei Kirino
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan
| | - Naomichi Matsumoto
- Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hideaki Nakajima
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
| |
Collapse
|
2
|
Yamazaki E. [Board-certified "hematologist" and "clinical laboratory physician": double jobbing-flow with the tide]. Rinsho Ketsueki 2023; 64:799-802. [PMID: 37673633 DOI: 10.11406/rinketsu.64.799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/08/2023]
Abstract
The Women Doctors Career Symposium entitled "Dreams: Female Hematologists' Talk" was held at the 84th Annual Meeting of the Japanese Society of Hematology. I would like to share my experience as a board-certified "hematologist" and "clinical laboratory physician." Certified clinical laboratory physician is one of the 19 fundamental areas in the Japanese Medical Specialty board, but the number is small, and it is also an area where hematologists can easily face challenges. It also allows you to balance career advancement and various life events. It is extremely difficult to forge one's own path, but it is relatively simple to take the advice of others and choose one's path. "We cannot direct the wind, but we can adjust the sails." This is one way to consider continuing a career.
Collapse
Affiliation(s)
- Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital
| |
Collapse
|
3
|
Boku S, Satake H, Ohta T, Mitani S, Kawakami K, Matsumoto T, Yamazaki E, Hasegawa H, Ikoma T, Uemura M, Yamaguchi T, Ishizuka Y, Kurokawa Y, Sakai D, Kawakami H, Shimokawa T, Tsujinaka T, Kato T, Satoh T, Kagawa Y. 440TiP TRESBIEN (OGSG 2101): Encorafenib, binimetinib and cetuximab for early relapse stage II/III BRAF V600E-mutated CRC. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Teshigawara-Tanabe H, Hagihara M, Aoki J, Koyama S, Takahashi H, Nakajima Y, Kunimoto H, Tachibana T, Miyazaki T, Matsumoto K, Tanaka M, Yamazaki E, Fujisawa S, Kanamori H, Taguri M, Nakajima H. Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. Hematology 2022; 27:620-628. [PMID: 35621915 DOI: 10.1080/16078454.2022.2052601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Objectives: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only curative treatment for myelodysplastic syndromes (MDS), although predicting post-transplant outcomes remains inconclusive. This study evaluated patients who underwent allo-HCT for MDS to identify prognostic factors and develop a clinical risk model.Methods: We evaluated 55 patients between June 2000 and March 2015 to identify prognostic factors and develop a model for three-year overall survival (OS) and event-free survival (EFS). Cox regression analysis was performed on four factors: age ≥55 years; Hematopoietic Cell Transplant-Comorbidity Index >2; intermediate or worse cytogenetic status based on revised International Prognostic Scoring System; and unrelated donor status associated with poor OS in the univariate analysis. A clinical risk model was constructed using the sum of the regression coefficients and evaluated using receiver operating characteristic analysis and five-fold cross-validation.Results: Patient median age was 51 (range: 30-67) years. Median follow-up was 45.8 (range: 1.27-193) months; the three-year OS and EFS rates were 61.8% and 56.4%, respectively. The areas under the curves (AUCs) for OS and EFS were 0.738 and 0.778, respectively, and the average AUC for 50 times five-fold cross-validation were 0.711 and 0.723 for three-year OS and EFS, respectively.Conclusion: A four-clinical-risk-factor model that could effectively predict post-transplantation outcomes and help decision-making in MDS treatment was developed.
Collapse
Affiliation(s)
- Haruka Teshigawara-Tanabe
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Maki Hagihara
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Jun Aoki
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - Satoshi Koyama
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Hiroyuki Takahashi
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Yuki Nakajima
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Hiroyoshi Kunimoto
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | | | - Takuya Miyazaki
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Kenji Matsumoto
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Masatsugu Tanaka
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Etsuko Yamazaki
- Department of Laboratory Medicine, Yokohama City University Hospital, Yokohama, Japan
| | - Shin Fujisawa
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - Heiwa Kanamori
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Masataka Taguri
- Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan
| | - Hideaki Nakajima
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| |
Collapse
|
5
|
Kato H, Miyakawa K, Ohtake N, Yamaoka Y, Yajima S, Yamazaki E, Shimada T, Goto A, Nakajima H, Ryo A. Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination. Vaccine 2022; 40:2652-2655. [PMID: 35370020 PMCID: PMC8960126 DOI: 10.1016/j.vaccine.2022.03.057] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 03/20/2022] [Accepted: 03/23/2022] [Indexed: 02/07/2023]
Abstract
To evaluate vaccine-induced humoral and cell-mediated immunity at 6 months after completion of two doses of BNT162b2 vaccination, immunoglobulin G against SARS-CoV-2 spike protein (SP IgG), 50% neutralizing antibody (NT50), and spot-forming cell (SFC) counts were evaluated by interferon-γ releasing ELISpot assay of 98 healthy subjects (median age, 43 years). The geometric mean titers of SP IgG and NT50 decreased from 95.2 (95% confidence interval (CI) 79.8–113.4) to 5.7 (95% CI 4.9–6.7) and from 680.4 (588.0–787.2) to 130.4 (95% CI 104.2–163.1), respectively, at 3 weeks and 6 months after the vaccination. SP IgG titer was negatively correlated with age and alcohol consumption. Spot-forming cell counts at 6 months did not correlate with age, gender, and other parameters of the patients. SP IgG, NT50, and SFC titers were elevated in the breakthrough infected subjects. Although the levels of vaccine-induced antibodies dramatically declined at 6 months after vaccination, a certain degree of cellular immunity was observed irrespective of the age.
Collapse
Affiliation(s)
- Hideaki Kato
- Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Kei Miyakawa
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Norihisa Ohtake
- Bioscience Division, Research and Development Department, Tosoh Corporation, Tokyo Research Center, Kanagawa, Japan; Advanced Medical Research Center, Yokohama City University, Yokohama, Japan
| | - Yutaro Yamaoka
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan; Life Science Laboratory, Technology and Development Division, Kanto Chemical Co, Inc., Isehara, Japan
| | - Satoshi Yajima
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Tomoko Shimada
- Nursing Department, Yokohama City University Hospital, Yokohama, Japan
| | - Atsushi Goto
- Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan
| | - Hideaki Nakajima
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Akihide Ryo
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan.
| |
Collapse
|
6
|
Yamazaki E. [Treatment strategy for acute lymphoblastic leukemia in adolescent and young adults]. Rinsho Ketsueki 2022; 63:826-832. [PMID: 35922954 DOI: 10.11406/rinketsu.63.826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA) is a relatively new concept that refers to patients aged 15-39 years with unique pathophysiology and requiring specific clinical care. Many clinical studies have revealed that treatment with the pediatric protocol has better disease-free and overall survival than the adult protocol for AYA-ALL. AYA-ALL survival was significantly improved from 30% with the adult regimen to 60-70% with the pediatric regimen. Two types of strategies are available to adapt pediatric regimens to AYA-ALL, a pediatric-inspired and a fully pediatric regimen. Determining the recommended strategy from these two strategies is difficult at this time. New knowledge of AYA-ALL-specific genetic characteristics provides new strategies for targetable ALL, especially Ph-like ALL. New immunotherapy has been approved for refractory and recurrent ALL; however, treatment results of AYA-ALL were improved by introducing the first line of immunotherapy in BCP-ALL, which may have a poor prognosis such as residual MRD. Pediatric and adult hematologists must work together to improve the prognosis of AYA-ALL.
Collapse
Affiliation(s)
- Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital
| |
Collapse
|
7
|
Teshigawara-Tanabe H, Hagihara M, Matsumura A, Takahashi H, Nakajima Y, Miyazaki T, Kamijo A, Yamazaki E, Fujimaki K, Matsumoto K, Nakajima H. Passenger lymphocyte syndrome after ABO-incompatible allogeneic hematopoietic stem cell transplantation; dynamics of ABO allo-antibody and blood type conversion. Hematology 2021; 26:835-839. [PMID: 34672906 DOI: 10.1080/16078454.2021.1986654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
Passenger lymphocyte syndrome (PLS) is a specific subtype of graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) characterized by an immune-mediated hemolysis caused by donor-derived B cells. However, precise nature of PLS has not been well characterized due to its rarity. We herein report two cases of PLS following ABO-incompatible HSCT whose clinical course and dynamics of anti-ABO allo-antibody and blood type conversion were closely examined. Both cases demonstrated acute hemolysis upon engraftment, and the presence of high titer allo-antibody against recipients' red blood cells (RBCs) helped us to reach the diagnosis of PLS. Hemolysis in both cases showed spontaneous improvement with prednisolone and supportive therapy including transfusion and fluid support. In one case with blood type O, the patient recursively developed PLS in the second and the third HSCT from ABO-mismatch donors, leading to a hypothesis that original blood type O may serve as a background for acute elevation of serum anti-ABO antibody and therefore a risk for developing PLS in multiple ABO-incompatible HSCTs. When hemolysis is noted following ABO-incompatible HSCTs, PLS should be considered and measurement of anti-ABO antibodies is warranted.
Collapse
Affiliation(s)
- Haruka Teshigawara-Tanabe
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Maki Hagihara
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Ayako Matsumura
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Hiroyuki Takahashi
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Yuki Nakajima
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Takuya Miyazaki
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Aki Kamijo
- Department of Transfusion and Cell Therapy, Yokohama City University Hospital, Yokohama, Japan
| | - Etsuko Yamazaki
- Department of Laboratory Medicine, Yokohama City University Hospital, Yokohama, Japan
| | | | - Kenji Matsumoto
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Hideaki Nakajima
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| |
Collapse
|
8
|
Wada-Irimada M, Mizuashi M, Takahashi T, Tojo G, Onami K, Shido K, Otake E, Yusa S, Tanita K, Yamazaki E, Aiba S, Yamasaki K. A retrospective study evaluating the outcomes of high-dose methylprednisolone pulse therapy for 483 patients with moderate-to-severe alopecia areata. Br J Dermatol 2021; 185:1267-1269. [PMID: 34254294 DOI: 10.1111/bjd.20644] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 07/09/2021] [Accepted: 07/10/2021] [Indexed: 11/29/2022]
Affiliation(s)
- M Wada-Irimada
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - M Mizuashi
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - T Takahashi
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - G Tojo
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan.,Dermatology, South Miyagi Medical Center, Shibata, Miyagi, 989-1253, Japan
| | - K Onami
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - K Shido
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - E Otake
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - S Yusa
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - K Tanita
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - E Yamazaki
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - S Aiba
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| | - K Yamasaki
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan
| |
Collapse
|
9
|
Funabashi R, Miyakawa K, Yamaoka Y, Yoshimura S, Yamane S, Jeremiah SS, Shimizu K, Ozawa H, Kawakami C, Usuku S, Tanaka N, Yamazaki E, Kimura H, Hasegawa H, Ryo A. Development of highly sensitive and rapid antigen detection assay for diagnosis of COVID-19 utilizing optical waveguide immunosensor. J Mol Cell Biol 2021; 13:763-766. [PMID: 34165565 PMCID: PMC8344664 DOI: 10.1093/jmcb/mjab037] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 05/01/2021] [Accepted: 05/12/2021] [Indexed: 01/16/2023] Open
Affiliation(s)
- Rikako Funabashi
- Department of Microbiology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
| | - Kei Miyakawa
- Department of Microbiology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
| | - Yutaro Yamaoka
- Department of Microbiology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.,Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Kanagawa, Japan
| | - Seiko Yoshimura
- Primary Care Testing Solution Development Department, Canon Medical Systems Corporation, Tochigi, Japan
| | - Satoshi Yamane
- Primary Care Testing Solution Development Department, Canon Medical Systems Corporation, Tochigi, Japan
| | | | - Kohei Shimizu
- Yokohama City Institute of Public Health, Kanagawa, Japan
| | - Hiroki Ozawa
- Yokohama City Institute of Public Health, Kanagawa, Japan
| | | | - Shuzo Usuku
- Yokohama City Institute of Public Health, Kanagawa, Japan
| | - Nobuko Tanaka
- Yokohama City Institute of Public Health, Kanagawa, Japan
| | - Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital, Kanagawa, Japan
| | - Hirokazu Kimura
- Department of Health Science, Gunma Paz University Graduate School, Gunma, Japan
| | - Hideki Hasegawa
- Influenza Research Center, National Institute of Infectious Diseases, Tokyo, Japan
| | - Akihide Ryo
- Department of Microbiology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
| |
Collapse
|
10
|
Yamaoka Y, Miyakawa K, Jeremiah SS, Funabashi R, Okudela K, Kikuchi S, Katada J, Wada A, Takei T, Nishi M, Shimizu K, Ozawa H, Usuku S, Kawakami C, Tanaka N, Morita T, Hayashi H, Mitsui H, Suzuki K, Aizawa D, Yoshimura Y, Miyazaki T, Yamazaki E, Suzuki T, Kimura H, Shimizu H, Okabe N, Hasegawa H, Ryo A. Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests. Cell Rep Med 2021; 2:100311. [PMID: 34027498 PMCID: PMC8126173 DOI: 10.1016/j.xcrm.2021.100311] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Revised: 04/02/2021] [Accepted: 05/13/2021] [Indexed: 12/24/2022]
Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic is a major global public health concern. Although rapid point-of-care testing for detecting viral antigen is important for management of the outbreak, the current antigen tests are less sensitive than nucleic acid testing. In our current study, we produce monoclonal antibodies (mAbs) that exclusively react with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and exhibit no cross-reactivity with other human coronaviruses, including SARS-CoV. Molecular modeling suggests that the mAbs bind to epitopes present on the exterior surface of the nucleocapsid, making them suitable for detecting SARS-CoV-2 in clinical samples. We further select the optimal pair of anti-SARS-CoV-2 nucleocapsid protein (NP) mAbs using ELISA and then use this mAb pair to develop immunochromatographic assay augmented with silver amplification technology. Our mAbs recognize the variants of concern (501Y.V1-V3) that are currently in circulation. Because of their high performance, the mAbs of this study can serve as good candidates for developing antigen detection kits for COVID-19.
Collapse
Affiliation(s)
- Yutaro Yamaoka
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan
- Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Kanagawa 259-1146, Japan
| | - Kei Miyakawa
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan
| | | | - Rikako Funabashi
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan
| | - Koji Okudela
- Department of Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan
| | - Sayaka Kikuchi
- Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Kanagawa 259-1146, Japan
| | - Junichi Katada
- Medical Systems Research & Development Center, FUJIFILM Corporation, Kaisei, Kanagawa 258-8538, Japan
| | - Atsuhiko Wada
- Medical Systems Research & Development Center, FUJIFILM Corporation, Kaisei, Kanagawa 258-8538, Japan
| | - Toshiki Takei
- Medical Systems Research & Development Center, FUJIFILM Corporation, Kaisei, Kanagawa 258-8538, Japan
| | - Mayuko Nishi
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan
| | - Kohei Shimizu
- Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan
| | - Hiroki Ozawa
- Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan
| | - Shuzo Usuku
- Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan
| | - Chiharu Kawakami
- Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan
| | - Nobuko Tanaka
- Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan
| | - Takeshi Morita
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan
| | - Hiroyuki Hayashi
- Division of Pathology, Yokohama Municipal Citizen’s Hospital, Yokohama, Kanagawa 221-0855, Japan
| | - Hideaki Mitsui
- Department of Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan
| | - Keita Suzuki
- Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Kanagawa 259-1146, Japan
| | - Daisuke Aizawa
- Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Kanagawa 259-1146, Japan
| | - Yukihiro Yoshimura
- Division of Infectious Disease, Yokohama Municipal Citizen’s Hospital, Yokohama, Kanagawa 221-0855, Japan
| | - Tomoyuki Miyazaki
- Department of Physiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan
| | - Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Kanagawa 236-0004, Japan
| | - Tadaki Suzuki
- Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo 162-8640, Japan
| | - Hirokazu Kimura
- School of Medical Technology, Faculty of Health Sciences, Gunma Paz University, Takasaki, Gunma 370-0006, Japan
| | - Hideaki Shimizu
- Division of Virology, Kawasaki City Institute for Public Health, Kawasaki, Kanagawa 210-0821, Japan
| | - Nobuhiko Okabe
- Division of Virology, Kawasaki City Institute for Public Health, Kawasaki, Kanagawa 210-0821, Japan
| | - Hideki Hasegawa
- Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan
| | - Akihide Ryo
- Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan
| |
Collapse
|
11
|
Watanabe S, Kobayashi N, Tomoyama A, Choe H, Yamazaki E, Inaba Y. Clinical characteristics and risk factors for culture-negative periprosthetic joint infections. J Orthop Surg Res 2021; 16:292. [PMID: 33941220 PMCID: PMC8091510 DOI: 10.1186/s13018-021-02450-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Accepted: 04/26/2021] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Culture-negative periprosthetic joint infections (PJIs) can complicate diagnosis and management of PJI. This study aimed to identify risk factors for culture-negative PJI and differences in clinical characteristics between culture-positive and culture-negative PJI group. METHODS This retrospective, cross-sectional study evaluated PJI cases obtained between January 2013 and October 2019 at our institution. These PJI cases were divided into culture-positive and culture-negative groups and then compared. The demographics, laboratory findings, and details of patient's clinical characteristics were investigated. Univariate and multivariate logistic regression analysis were performed to investigate risk factors for culture-negative PJI. RESULTS A total of 109 PJI cases were included in the analysis: 82 (75%) culture-positive and 27 (25%) culture-negative. The mean serum white blood cell (WBC) count, C-reactive protein level, and erythrocyte sedimentation rate in the culture-negative group were significantly lower than those in the culture-positive group (p < 0.05). There were no significant differences between the two groups regarding history of prior antibacterial administration or treatment success rates. Multivariate analysis identified a low serum WBC count as a risk factor for culture-negative PJI (odds ratio = 0.78; 95% confidence interval [CI] = 0.63-0.97; p = 0.027). CONCLUSIONS A low serum WBC count is a risk factor for culture-negative PJI, but prior antimicrobial therapy is not. The results suggest that PJI cases with lower levels of systemic inflammation are likely to be culture-negative; therefore, the possibility of a culture-negative result should be considered in suspected cases of PJI with low inflammatory markers, regardless of prior antibiotic exposure.
Collapse
Affiliation(s)
- Shintaro Watanabe
- Department of Orthopedic Surgery, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa Japan
| | - Naomi Kobayashi
- Department of Orthopedic Surgery, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama City, Kanagawa Japan
| | - Akito Tomoyama
- Department of Clinical Laboratory Center, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa Japan
| | - Hyonmin Choe
- Department of Orthopedic Surgery, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa Japan
| | - Etsuko Yamazaki
- Department of Clinical Laboratory Center, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa Japan
| | - Yutaka Inaba
- Department of Orthopedic Surgery, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa Japan
| |
Collapse
|
12
|
Fukushima Y, Yamamoto Y, Yamazaki E, Imai K, Kagawa Y, Takahashi Y. Change in the pharmacokinetics of lacosamide before, during, and after pregnancy. Seizure 2021; 88:12-14. [PMID: 33774498 DOI: 10.1016/j.seizure.2021.03.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Revised: 03/08/2021] [Accepted: 03/13/2021] [Indexed: 11/26/2022] Open
Affiliation(s)
- Yutaro Fukushima
- Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Shizuoka, 420-8688, Japan
| | - Yoshiaki Yamamoto
- Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Shizuoka, 420-8688, Japan; Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Shizuoka, 422-8526, Japan.
| | - Etsuko Yamazaki
- Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Shizuoka, 420-8688, Japan
| | - Katsumi Imai
- Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Shizuoka, 420-8688, Japan
| | - Yoshiyuki Kagawa
- Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Shizuoka, 422-8526, Japan; Laboratory of Clinical Pharmacokinetics and Drug Safety, Shizuoka General Hospital, 4-27-1 Kita Ando, Shizuoka, 420-8527, Japan
| | - Yukitoshi Takahashi
- Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Shizuoka, 420-8688, Japan; Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Shizuoka, 422-8526, Japan
| |
Collapse
|
13
|
Kubo S, Ohtake N, Miyakawa K, Jeremiah SS, Yamaoka Y, Murohashi K, Hagiwara E, Mihara T, Goto A, Yamazaki E, Ogura T, Kaneko T, Yamanaka T, Ryo A. Development of an Automated Chemiluminescence Assay System for Quantitative Measurement of Multiple Anti-SARS-CoV-2 Antibodies. Front Microbiol 2021; 11:628281. [PMID: 33519790 PMCID: PMC7843449 DOI: 10.3389/fmicb.2020.628281] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Accepted: 12/17/2020] [Indexed: 01/19/2023] Open
Abstract
Objectives Serological tests for COVID-19 have been instrumental in studying the epidemiology of the disease. However, the performance of the currently available tests is plagued by the problem of variability. We have developed a high-throughput serological test capable of simultaneously detecting total immunoglobulins (Ig) and immunoglobulin G (IgG) against nucleocapsid protein (NP) and spike protein (SP) and report its performance in detecting COVID-19 in clinical samples. Methods We designed and prepared reagents for measuring NP-IgG, NP-Total Ig, SP-IgG, and SP-Total Ig (using N-terminally truncated NP (ΔN-NP) or receptor-binding domain (RBD) antigen) dedicated automated chemiluminescent enzyme immunoassay analyzer AIA-CL1200. After determining the basal thresholds based on 17 sera obtained from confirmed COVID-19 patients and 600 negative sera, the clinical validity of the assay was evaluated using independent 202 positive samples and 1,000 negative samples from healthy donors. Results All of the four test parameters showed 100% specificity individually (1,000/1,000; 95%CI, 99.63–100). The sensitivity of the assay increased proportionally to the elapsed time from symptoms onset, and all the tests achieved 100% sensitivity (153/153; 95%CI, 97.63–100) after 13 days from symptoms onset. NP-Total Ig was the earliest to attain maximal sensitivity among the other antibodies tested. Conclusion Our newly developed serological testing exhibited 100% sensitivity and specificity after 13 days from symptoms onset. Hence, it could be used as a reliable method for accurate detection of COVID-19 patients and to evaluate seroprevalence and possibly for surrogate assessment of herd immunity.
Collapse
Affiliation(s)
- Sousuke Kubo
- Department of Microbiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Norihisa Ohtake
- Bioscience Division, Reagent Development Department, Tosoh Corporation, Kanagawa, Japan.,Advanced Medical Research Center, Yokohama City University, Yokohama, Japan
| | - Kei Miyakawa
- Department of Microbiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | | | - Yutaro Yamaoka
- Department of Microbiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Kanagawa, Japan
| | - Kota Murohashi
- Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Eri Hagiwara
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Takahiro Mihara
- Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan
| | - Atsushi Goto
- Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan
| | - Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Takashi Ogura
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
| | - Takeshi Kaneko
- Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Takeharu Yamanaka
- Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan.,Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Akihide Ryo
- Department of Microbiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
14
|
Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito AM, Hirakawa A, Kiyoi H, Matsumura I, Miyazaki Y. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. Int J Hematol 2020; 113:395-403. [PMID: 33230647 DOI: 10.1007/s12185-020-03032-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Revised: 10/24/2020] [Accepted: 10/27/2020] [Indexed: 11/25/2022]
Abstract
This phase 1/2 study aimed to identify the maximum tolerated dose, the recommended phase 2 dose (RP2D), and efficacy of the clofarabine, etoposide, and cyclophosphamide combination regimen in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Patients aged ≥ 15 years with relapsed/refractory ALL were enrolled. Escalating doses of clofarabine (20-30 mg/m2/day × 5 days), etoposide (50-100 mg/m2/day × 5 days), and cyclophosphamide (200-440 mg/m2/day × 5 days) were administered. Dose-limiting toxicity was defined as Grade 3 or more non-hematological toxicities and others. A total of 18 patients (B-ALL; n = 13, T-ALL; n = 5) were recruited in phase 1; however, the protocol was amended to close study without proceeding to phase 2. Three patients were enrolled in cohort 1, three in cohort 2, six in cohort 3, and six in cohort 4. The RP2D of clofarabine, etoposide, and cyclophosphamide was 30, 100, and 440 mg/m2 daily, respectively. Complete remission (CR) was achieved in four patients (22%) and CR without platelet recovery in four patients (22%), with an overall response rate of 44%. The RP2D of the combination therapy was successfully determined in this study.
Collapse
Affiliation(s)
- Takeshi Saito
- Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
| | - Yoshihiro Hatta
- Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan
| | - Fumihiko Hayakawa
- Division of Cellular and Genetic Sciences, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Tsutomu Takahashi
- Department of Oncology/Hematology, Shimane University Hospital, Izumo, Japan
| | - Maki Hagihara
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Hiroatsu Iida
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan
| | | | - Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Isamu Sugiura
- Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan
| | - Tohru Murayama
- Department of Hematology, Hyogo Cancer Center, Akashi, Japan
| | - Toru Sakura
- Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan
| | - Naoki Mori
- Department of Hematology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - Kiyotoshi Imai
- Department of Hematology, Otaru General Hospital, Otaru, Japan
| | - Yuichi Yahagi
- Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
| | - Yoshiko Atsuta
- Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan
| | - Akiko Moriya Saito
- Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
| | - Akihiro Hirakawa
- Division of Biostatics and Data Science, Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan
| | - Hitoshi Kiyoi
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Itaru Matsumura
- Department of Hematology and Rheumatology, Kindai University Hospital, Faculty of Medicine, Osaka, Japan
| | - Yasushi Miyazaki
- Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
| |
Collapse
|
15
|
Hatta Y, Hayakawa F, Yamazaki E. JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). Int J Hematol 2020; 112:439-458. [PMID: 32812190 DOI: 10.1007/s12185-020-02965-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Accepted: 08/03/2020] [Indexed: 10/23/2022]
Affiliation(s)
- Yoshihiro Hatta
- Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
| | - Fumihiko Hayakawa
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
| |
Collapse
|
16
|
Nagahama Y, Nozaki J, Sakurai G, Yajima S, Kaneko N, Yamazaki E, Matsuda M. Clinical application of a new latex photometric immunoassay reagent, LPIA-GENESIS D-dimer, and its performance in patient-derived plasma samples. Int J Lab Hematol 2020; 42:299-307. [PMID: 32112525 PMCID: PMC7318163 DOI: 10.1111/ijlh.13169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 01/31/2020] [Accepted: 02/03/2020] [Indexed: 11/28/2022]
Abstract
Introduction We previously reported an antibody MIF‐220 that recognizes a specific structure induced on the surface of thrombin‐activated E‐domain of one fibrin molecule bound with the D‐domains of other fibrinogen/fibrin molecules. Utilizing MIF‐220, we produced a test kit for cross‐linked fibrin degradation products (XDP), LPIA‐GENESIS D‐dimer (LG‐DD), and evaluated basic performance characteristics for clinical application. We then attempted to apply LG‐DD to see its eligibility in clinical plasma samples. Method The characteristic performances requested for clinical use were studied including limit of quantitation, within‐run imprecision, day‐to‐day imprecision, antigen excess, interference study, and method comparison with LPIAACE‐Ddimer (ACE‐DD) available on the market. Results The performance characteristics were all satisfactory. Extraordinarily high concentrations of XDP are occasionally obtained by ACE‐DD in samples with collection problems, but not by LG‐DD, indicating that a certain XDP species present in the former was not measured by LG‐DD. Structural studies suggested that the “B‐b” set of polymerization sites must be involved as well in the maintenance of cross‐linked fibrin in vivo. Conclusion LG‐DD was able to measure a wide range of XDP, that is, 0.20‐35.0 μg FEU/mL that covers the levels of XDP in most of the clinical samples. LG‐DD was found to almost avoid false‐positive results noticed in samples as mentioned above, and this feature seems to be preferable to established kits for the measurement of XDP.
Collapse
Affiliation(s)
- Yutaka Nagahama
- IVD Business Segment, LSI Medience Corporation, Tokyo, Japan
| | - Junko Nozaki
- IVD Business Segment, LSI Medience Corporation, Tokyo, Japan
| | - George Sakurai
- IVD Business Segment, LSI Medience Corporation, Tokyo, Japan
| | - Satoshi Yajima
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Noriko Kaneko
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | | |
Collapse
|
17
|
Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, Shono K, Tanaka M, Tsukamoto S, Mori T, Yamazaki E, Najima Y, Hangaishi A, Hoshino T, Watanabe R, Matsumoto K, Okamoto S. Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. Am J Hematol 2020; 95:251-257. [PMID: 31804748 DOI: 10.1002/ajh.25693] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2019] [Revised: 11/29/2019] [Accepted: 12/02/2019] [Indexed: 11/10/2022]
Abstract
The optimal pre-transplant conditioning for aplastic anemia (AA) remains unclear. We performed a prospective study on allogeneic transplantation from a related or unrelated donor for adult patients with AA. We assessed whether reduced-dose cyclophosphamide (CY) could decrease toxicity while maintaining engraftment, and low-dose thymoglobulin could safely prevent graft-vs-host disease (GVHD). The pre-transplant conditioning regimen consisted of fludarabine 120 mg/m2 , CY 100 mg/kg, and thymoglobulin 2.5 mg/kg with or without 2 Gy of total body irradiation. Twenty-seven patients with a median age of 36 years were analyzed. Sixteen patients received graft from related donors. The stem cell source was bone marrow in 26 patients. All of the patients but one, who died early, achieved neutrophil engraftment at a median of 19 days. Mixed chimerism was observed in six and five patients at days 30 and 90, respectively. Only one patient experienced secondary engraftment failure with complete donor-type chimerism. None of the patients developed severe acute GVHD. The cumulative incidence of chronic GVHD was 37.7% at 1 year. The overall survival rate was 96.3% at 1 year and 3 years. A high EB virus-DNA load was detected in one patient at days 60. No one developed EBV-lymphoproliferative disorder within a year. The results suggest that the conditioning regimen in this study was safe and effective. However, relatively high incidence of chronic GVHD needs further improvement.
Collapse
Affiliation(s)
- Shinichi Kako
- Division of HematologyJichi Medical University Saitama Medical Center Saitama Japan
| | - Yoshinobu Kanda
- Division of HematologyJichi Medical University Saitama Medical Center Saitama Japan
| | - Makoto Onizuka
- Department of Hematology and OncologyTokai University School of Medicine Kanagawa Japan
| | - Nobuyuki Aotsuka
- Division of Hematology‐OncologyJapanese Red Cross Society Narita Hospital Chiba Japan
| | - Kensuke Usuki
- Department of HematologyNTT Medical Center Tokyo Tokyo Japan
| | - Takayoshi Tachibana
- Department of HematologyYokohama City University Medical Center Yokohama Japan
| | - Takeshi Kobayashi
- Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases CenterKomagome Hospital Tokyo Japan
| | - Jun Kato
- Division of Hematology, Department of MedicineKeio University School of Medicine Tokyo Japan
| | - Shingo Yano
- Division of Clinical Oncology and Hematology, Department of Internal MedicineThe Jikei University School of Medicine Tokyo Japan
| | - Hiroaki Shimizu
- Department of Medicine and Clinical ScienceGunma University Gunma Japan
| | - Katsuhiro Shono
- Department of HematologyChiba Aoba Municipal Hospital Chiba Japan
| | | | | | - Takehiko Mori
- Division of Hematology, Department of MedicineKeio University School of Medicine Tokyo Japan
| | - Etsuko Yamazaki
- Department of Hematology and Clinical ImmunologyYokohama City University School of Medicine Kanagawa Japan
| | - Yuho Najima
- Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases CenterKomagome Hospital Tokyo Japan
| | - Akira Hangaishi
- Department of HematologyNTT Medical Center Tokyo Tokyo Japan
| | - Takumi Hoshino
- Leukemia Research CenterSaiseikai Maebashi Hospital Gunma Japan
| | - Reiko Watanabe
- Department of Hematology, Saitama Medical CenterSaitama Medical University Saitama Japan
| | - Kenji Matsumoto
- Department of HematologyKanagawa Cancer Center Kanagawa Japan
- Department of Hematology and Clinical ImmunologyYokohama City University School of Medicine Kanagawa Japan
| | - Shinichiro Okamoto
- Division of Hematology, Department of MedicineKeio University School of Medicine Tokyo Japan
| | | |
Collapse
|
18
|
Watanabe S, Kobayashi N, Tomoyama A, Choe H, Yamazaki E, Inaba Y. Differences in Diagnostic Properties Between Standard and Enrichment Culture Techniques Used in Periprosthetic Joint Infections. J Arthroplasty 2020; 35:235-240. [PMID: 31522855 DOI: 10.1016/j.arth.2019.08.035] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Revised: 07/25/2019] [Accepted: 08/14/2019] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Culture-negative infections can complicate the diagnosis and management of orthopedic infections, particularly periprosthetic joint infections (PJIs). This study aimed to identify differences in rate of detection of infection and organisms between cultured using standard and enriched methods. METHODS This retrospective, cross-sectional study evaluated PJI samples obtained between January 2013 and December 2017 at Yokohama City University Hospital. Samples were assessed using standard and enrichment culture techniques. White blood cell counts, C-reactive protein levels, type of microorganism (coagulase-positive or coagulase-negative), and methicillin-resistant Staphylococcus were investigated. RESULTS A total of 151 PJI samples were included in the analysis; of these, 68 (45.0%) were positive after standard culture while 83 (55.0%) were positive only after enrichment culture. The mean white blood cell counts and C-reactive protein levels were significantly lower in the enrichment culture group than in the standard culture group (P < .01). The rate of methicillin-resistant Staphylococcus and coagulase-negative Staphylococci was significantly higher in the enrichment culture group than in the standard culture group (P < .01). CONCLUSION The enrichment culture method has a higher rate of detection of infection than standard culture techniques and should, therefore, be considered when diagnosing orthopedic infections, particularly PJI.
Collapse
Affiliation(s)
- Shintaro Watanabe
- Department of Orthopedic Surgery, Yokohama City University, Yokohama, Japan
| | - Naomi Kobayashi
- Department of Orthopedic Surgery, Yokohama City University Medical Center, Yokohama, Japan
| | - Akito Tomoyama
- Department of Clinical Laboratory Center, Yokohama City University, Yokohama, Japan
| | - Hyonmin Choe
- Department of Orthopedic Surgery, Yokohama City University, Yokohama, Japan
| | - Etsuko Yamazaki
- Department of Clinical Laboratory Center, Yokohama City University, Yokohama, Japan
| | - Yutaka Inaba
- Department of Orthopedic Surgery, Yokohama City University, Yokohama, Japan
| |
Collapse
|
19
|
Koyama S, Fujita H, Shimosato T, Kamijo A, Ishiyama Y, Yamamoto E, Ishii Y, Hattori Y, Hagihara M, Yamazaki E, Tomita N, Nakajima H. Septicemia from Lactobacillus rhamnosus GG, from a Probiotic Enriched Yogurt, in a Patient with Autologous Stem Cell Transplantation. Probiotics Antimicrob Proteins 2019; 11:295-298. [PMID: 29455334 DOI: 10.1007/s12602-018-9399-6] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Probiotic-rich foods are consumed without much restriction. We report here, a case of septic shock caused by yogurt derived Lactobacillus species in a 54-year-old male patient with acute promyelocytic leukemia, in second complete remission, and who was an autologous stem cell transplantation recipient. He received high dose chemotherapy and autologous peripheral blood stem cell transplantation. He ingested commercially available probiotic-enriched yogurt because of severe diarrhea. One week later, he developed septic shock, and the pathogen was determined by strain-specific PCR analysis as Lactobacillus rhamnosus GG (ATCC 53103), which was found to be identical with the strain in the yogurt he consumed. Thus, because even low virulent Lactobacilli in the probiotic products can be pathogenic in the compromised hosts, ingestion of such products should be considered with caution in neutropenic patients with severe diarrhea, such as stem cell transplantation recipients.
Collapse
Affiliation(s)
- Satoshi Koyama
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Hiroyuki Fujita
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
- Department of Hematology, Saiseikai Yokohama Nanbu Hospital, 3-2-10 Konandai Konanku, Yokohama, 234-0054, Japan.
| | - Takeshi Shimosato
- Research Center for Fungal and Microbial Dynamism, Shinshu University, Kamiina, Japan
| | - Aki Kamijo
- Department of Transfusion, Yokohama City University Hospital, Yokohama, Japan
| | - Yasufumi Ishiyama
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Eri Yamamoto
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - Yoshimi Ishii
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - Yukako Hattori
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
- Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan
| | - Maki Hagihara
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| | - Etsuko Yamazaki
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
- Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Naoto Tomita
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
- Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
| | - Hideaki Nakajima
- Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
| |
Collapse
|
20
|
Ando T, Fujisawa S, Teshigawara H, Ogusa E, Ishii Y, Miyashita K, Motohashi K, Miyazaki T, Tachibana T, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Fujita H, Kanamori H, Yamazaki E, Nakajima H. Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia. Int J Hematol 2019; 109:673-683. [PMID: 30963469 DOI: 10.1007/s12185-019-02647-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2018] [Revised: 03/31/2019] [Accepted: 04/02/2019] [Indexed: 01/22/2023]
Abstract
We hypothesized that treatment-related weight loss is associated with worse outcomes following HSCT. Overall, 184 patients with AML who underwent induction therapy were classified according to d-BMI (BMI at transplant minus BMI at diagnosis) (kg/m2) as < -2, - 2 to + 2, and > + 2. At 1 year, OS was 67.9% (95% CI, 60.7-74.2), DFS was 64.1% (95% CI, 56.7-70.6), and GRFS was 40.2% (95% CI, 33.1-47.2). For d-BMI groups < - 2, - 2 to + 2, and > + 2, GRFS at 1 year was 16.1% (95% CI, 5.1-31.4), 45.4% (95% CI, 36.4-53.7), and 41.7% (95% CI, 22.2-60.1), respectively (P = 0.0067). Multivariate analysis showed that both worse OS (HR, 1.78; 95% CI, 1.02-3.14; P = 0.007) and GRFS (HR, 2.34; 95% CI, 1.26-4.35; P = 0.007) were associated with reduced BMI (d-BMI < - 2). Treatment-related weight reduction in AML was associated with poor outcome after HSCT.
Collapse
Affiliation(s)
- Taiki Ando
- Department of Stem Cell and Immune Regulation, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. .,Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama, Kanagawa, Japan.
| | - Shin Fujisawa
- Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama, Kanagawa, Japan
| | - Haruka Teshigawara
- Department of Stem Cell and Immune Regulation, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.,Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan
| | - Eriko Ogusa
- Department of Stem Cell and Immune Regulation, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.,Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama, Kanagawa, Japan
| | - Yoshimi Ishii
- Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama, Kanagawa, Japan
| | - Kazuho Miyashita
- Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama, Kanagawa, Japan
| | - Kenji Motohashi
- Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama, Kanagawa, Japan
| | - Takuya Miyazaki
- Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan
| | | | - Maki Hagihara
- Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan
| | - Kenji Matsumoto
- Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan
| | - Masatsugu Tanaka
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Chizuko Hashimoto
- Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan
| | | | | | - Jun Taguchi
- Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan
| | - Hiroyuki Fujita
- Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan
| | - Heiwa Kanamori
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Etsuko Yamazaki
- Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan.,Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Hideaki Nakajima
- Department of Stem Cell and Immune Regulation, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.,Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan
| | | |
Collapse
|
21
|
Mohri H, Yamazaki E, Suzuki Z, Takano T, Yokota S, Okubo T. Autoantibody Selectively Inhibits Binding of von Willebrand Factor to Glycoprotein Ib. Recognition Site Is Located in the A1 Loop of von Willebrand Factor. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1656047] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryA 20-year-old man with severe von Willebrand disease recently presented a progressive bleeding tendency, characterized recurrent subcutaneous hemorrhages and cerebral hemorrhage. Mixing and infusion studies suggested the presence of an inhibitor directed against vWF:RCo activity of von Willebrand factor (vWF) without significant inhibition of the FVIII:C. The inhibitor was identified as an antibody of IgG class. The inhibitor inhibited the interaction of vWF in the presence of ristocetin and that of asialo-vWF with GPIb while it partially blocked botrocetin-mediated interaction of vWF to GPIb. The inhibitor reacted with native vWF, the 39/34kDa fragment (amino acids [aa] 480/ 481-718) and the recombinant vWF fragment (MalE-rvWF508-704), but not with Fragment III-T2 (heavy chains, aa 273-511; light chains, aa 674-728). A synthetic peptide (aa 514-542) did not inhibit vWF-inhibitor complex formation. We conclude that this is the first autoantibody of class IgG from human origin that recognizes the sequence in the A1 loop of vWF, resulting in a virtual absence of functional vWF and a concomitant severe bleeding tendency although recognition site is different from the residues 514-542 which is crucial for vWF-GPIb interaction.
Collapse
Affiliation(s)
- Hiroshi Mohri
- The First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama
| | - Etsuko Yamazaki
- The First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama
| | - Zekou Suzuki
- The Department of Clinical Laboratory, Iwate Medical School, Morioka
| | - Toshikuni Takano
- The Department of Pediatrics, Iwate Medical School, Morioka, Japan
| | - Shumpei Yokota
- The Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan
| | - Takao Okubo
- The First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama
| |
Collapse
|
22
|
Nakasone H, Terasako-Saito K, Hirano T, Wake A, Shimizu S, Kurita N, Yamazaki E, Usuki K, Akazawa K, Kanda J, Minauchi K, Yamamoto G, Tanimoto S, Kamoshita M, Yokoyama Y, Miyaoka E, Ota S, Kako S, Izutsu K, Kanda Y. Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study). Hematol Oncol 2017; 36:202-209. [PMID: 28681529 DOI: 10.1002/hon.2452] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2017] [Revised: 05/30/2017] [Accepted: 06/05/2017] [Indexed: 11/06/2022]
Abstract
Complete response (CR) after treatment for multiple myeloma is associated with superior progression-free survival (PFS). Multiple myeloma patients were prospectively recruited for induction treatment with bortezomib and dexamethasone (BD) followed by autologous hematopoietic cell transplantation (auto-HCT) between 2010 and 2012. If patients did not achieve CR after auto-HCT, BD consolidation therapy was added to target CR. After the BD induction phase (n = 46), greater than or equal to CR was achieved in 4 patients (8%). After auto-HCT (n = 34), greater than or equal to CR was achieved in 9 patients (20%) and very good partial response (VGPR) was achieved in 11 (24%). Of the 24 patients who received auto-HCT and whose response was less than CR, 21 received BD consolidation therapy for a median of 4 courses. Finally, the maximum response with or without BD consolidation was greater than or equal to CR in 19 (41%), VGPR in 7 (15%), and PR in 6 (13%). Through BD consolidation, CR was achieved in 8 of 11 patients with post-HCT VGPR and in 2 of 12 patients with post-HCT PR. In total, 4 year PFS and overall survival were 43 and 80%, respectively. After adjusting for clinical factors, there was no difference in PFS between CR patients after auto-HCT and BD consolidation, while patients with less than or equal to VGPR after consolidation had a significantly lower PFS. Patients with post-HCT CR showed good PFS, and targeting CR through BD consolidation could improve the CR rate. It would be worthwhile to prospectively compare the efficacy of consolidation only for patients who failed to achieve CR to a universal consolidation strategy.
Collapse
Affiliation(s)
- Hideki Nakasone
- Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
| | - Kiriko Terasako-Saito
- Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
| | - Teiichi Hirano
- Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
| | - Atsushi Wake
- Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.,Okinaka Memorial Institute of Medical Research, Tokyo, Japan
| | - Seiichi Shimizu
- Department of Hematology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan
| | - Naoki Kurita
- Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Etsuko Yamazaki
- Department of Hematology and Clinical Immunology, Yokohama City University Hospital, Yokohama, Japan.,Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
| | - Kensuke Usuki
- Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan
| | - Kohei Akazawa
- Department of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - Junya Kanda
- Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
| | | | - Go Yamamoto
- Department of Hematology, Toranomon Hospital, Tokyo, Japan
| | - Shiori Tanimoto
- Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
| | - Masaharu Kamoshita
- Department of Hematology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan
| | - Yasuhisa Yokoyama
- Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Etsuo Miyaoka
- Department of Mathematics, Faculty of Science Division II, Tokyo University of Science, Tokyo, Japan
| | - Shuichi Ota
- Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan
| | - Shinichi Kako
- Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
| | - Koji Izutsu
- Department of Hematology, Toranomon Hospital, Tokyo, Japan
| | - Yoshinobu Kanda
- Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan
| |
Collapse
|
23
|
Piao HT, Jiao XC, Gai N, Chen S, Lu GH, Yin XC, Yamazaki E, Yamashita N, Tan KY, Yang YL, Pan J. Perfluoroalkyl substances in waters along the Grand Canal, China. Chemosphere 2017; 179:387-394. [PMID: 28390306 DOI: 10.1016/j.chemosphere.2017.03.133] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2016] [Revised: 03/29/2017] [Accepted: 03/30/2017] [Indexed: 06/07/2023]
Abstract
The Grand Canal, also known as the Beijing-Hangzhou Grand Canal, is a UNESCO World Heritage Site and the longest canal in the world. It is an important trunk line of the South-to-North Water Diversion Project in China. The contamination status and spatial distributions of perfluoroalky substances (PFASs) in waters of the Grand Canal were investigated. The total concentrations of PFASs (∑PFASs) range from 7.8 ng/L to 218.0 ng/L, with high ∑PFASs occurring in the southern part of the Grand Canal which is located in a highly urbanized and economically developed region. The dominance of PFOA showed a decreasing trend toward north while shorter chain homologue proportions increased in the northern part of the Canal which mainly traverses underdeveloped and rural areas in Eastern China. Positive correlations were observed between ∑PFASs and the population density as well as GDP per capita. Intersection with large rivers may affect the contamination levels and composition of PFASs in the water of the Grand Canal near the intersection sites.
Collapse
Affiliation(s)
- H T Piao
- National Research Center for Geo-analysis (NRCGA), 26 Baiwanzhuang Avenue, Xicheng District, Beijing, 100037, China
| | - X C Jiao
- National Research Center for Geo-analysis (NRCGA), 26 Baiwanzhuang Avenue, Xicheng District, Beijing, 100037, China.
| | - N Gai
- National Research Center for Geo-analysis (NRCGA), 26 Baiwanzhuang Avenue, Xicheng District, Beijing, 100037, China
| | - S Chen
- National Research Center for Geo-analysis (NRCGA), 26 Baiwanzhuang Avenue, Xicheng District, Beijing, 100037, China
| | - G H Lu
- National Research Center for Geo-analysis (NRCGA), 26 Baiwanzhuang Avenue, Xicheng District, Beijing, 100037, China
| | - X C Yin
- College of Environmental Sciences and Engineering, Qingdao University, Qingdao, 266071, China
| | - E Yamazaki
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki, 305-8569, Japan
| | - N Yamashita
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki, 305-8569, Japan
| | - K Y Tan
- National Research Center for Geo-analysis (NRCGA), 26 Baiwanzhuang Avenue, Xicheng District, Beijing, 100037, China
| | - Y L Yang
- National Research Center for Geo-analysis (NRCGA), 26 Baiwanzhuang Avenue, Xicheng District, Beijing, 100037, China
| | - J Pan
- National Research Center for Geo-analysis (NRCGA), 26 Baiwanzhuang Avenue, Xicheng District, Beijing, 100037, China.
| |
Collapse
|
24
|
Ge H, Yamazaki E, Yamashita N, Taniyasu S, Ogata A, Furuuchi M. Particle size specific distribution of perfluoro alkyl substances in atmospheric particulate matter in Asian cities. Environ Sci Process Impacts 2017; 19:549-560. [PMID: 28276550 DOI: 10.1039/c6em00564k] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Seasonal and local characteristics of perfluorinated alkylated substances (PFASs) were examined using size-segregated particles including an ultrafine range. The examination included sampling and analysis of ambient particles collected at four sites located in different environments in three different countries, Japan (Kanazawa and Okinawa), Hong Kong and India. To minimize the evaporation artefacts derived from PFASs during the sampling, an air sampler that permitted particles smaller than 0.1 μm (PM0.1) to be separated at a moderate pressure drop (<5-15 kPa), was used for all of the air sampling procedures. In the case of Kanazawa, a local city in Japan, the concentration of PFASs was found to be dominated by carboxylates, especially PFOA, PFNA and PFDA regardless of the particle size and sampling period. Ultrafine particles were found to be the largest contributor to the mass fraction of PFCAs, while the maximum PFOS mass fractions were determined to be in the coarse-sized fractions. The seasonal difference in the total PFAS concentration can be largely attributed to precipitation. The results were basically similar for all sites that were examined. The type of land use may be a more influencing factor on the mass fraction of the PFASs than the country of origin. The dependency of PFAS mass fraction on the specific surface of the particle suggests that ultrafine PFAS particles are segregated, not only by gas deposition but could also be segregated by a mechanism involving compositional dependence or the primary source of the particles. Other possible sources of PFASs, other than from traffic are also possible.
Collapse
Affiliation(s)
- H Ge
- School of Environmental Design, College of Science and Engineering, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
| | | | | | | | | | | |
Collapse
|
25
|
Abstract
Multiple myeloma (MM) has been diagnosed based on the International Myeloma Working Group (IMWG) diagnostic criteria since 2003. In 2014, the IMWG updated these diagnostic criteria to add three specific biomarkers, i.e., 1) Clonal bone marrow plasma cell percentage ≥60%; 2) Involved: uninvolved serum free light chain ratio ≥100; 3) >1 focal lesion on MRI studies, based on CRAB features (hypercalcemia, renal failure, anemia, and bone lesions). An early diagnosis of MM can be made, allowing timely anti-MM treatment, in patients with the ultra-high-risk smoldering form of this disease. This review focuses on the new IMWG diagnostic criteria for MM and evaluation of patients newly diagnosed with MM.
Collapse
Affiliation(s)
- Etsuko Yamazaki
- Clinical Laboratory Department, Yokohama City University Hospital
| |
Collapse
|
26
|
Ando T, Yamazaki E, Ogusa E, Ishii Y, Yamamoto W, Motohashi K, Tachibana T, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Fujita H, Kanamori H, Fujisawa S, Nakajima H. Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. Int J Hematol 2017; 105:623-630. [DOI: 10.1007/s12185-017-2183-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 01/12/2017] [Accepted: 01/12/2017] [Indexed: 11/29/2022]
|
27
|
Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Yamazaki E, Koharazawa H, Takemura S, Tomita N, Sakai R, Motomura S, Nakajima H. Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int J Lab Hematol 2016; 39:112-117. [PMID: 27885817 DOI: 10.1111/ijlh.12592] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 09/10/2016] [Indexed: 11/30/2022]
Abstract
INTRODUCTION The prognostic value of serum ferritin level in patients with peripheral T-cell lymphoma (PTCL) remains unknown. METHODS We retrospectively analyzed clinical data from 78 consecutive patients with newly diagnosed PTCL that were treated with anthracycline-containing regimens between 1998 and 2011. RESULTS The patients consisted of 50 males and 28 females with a median age of 64 years (range, 16-83 years). The subtypes of PTCL were 39 PTCL, not otherwise specified and 39 angioimmunoblastic T-cell lymphoma (AITL). The median observation period for the surviving patients was 50 months. The overall survival (OS) was poorer in patients with serum ferritin level above the upper normal limit (n = 28), compared with patients with serum ferritin level within normal range (n = 50; 4-year OS: 23% vs. 72%; P < 0.001). In the multivariate analysis, poor performance status (P = 0.006) and elevated serum ferritin level (P = 0.018) were independent risk factors for poor OS. CONCLUSION Serum ferritin level is a useful prognostic marker for PTCL.
Collapse
Affiliation(s)
- S Koyama
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - S Fujisawa
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - R Watanabe
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - M Itabashi
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - D Ishibashi
- Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan
| | - Y Ishii
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Y Hattori
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Y Nakajima
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - K Motohashi
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - H Takasaki
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - R Kawasaki
- Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan
| | - C Hashimoto
- Department of Hematology, Yamato Municipal Hospital, Yamato, Japan
| | - E Yamazaki
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - H Koharazawa
- Department of Hematology, Yamato Municipal Hospital, Yamato, Japan
| | - S Takemura
- Department of Internal Medicine, Yokohama Ekisaikai Hospital, Yokohama, Japan
| | - N Tomita
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - R Sakai
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - S Motomura
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - H Nakajima
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
28
|
Matsumoto S, Shibuya H, Tatera S, Yamazaki E, Suzuki S. Comparison of CT Findings in Non-Hodgkin Lymphoma and Squamous Cell Carcinoma of the Maxillary Sinus. Acta Radiol 2016. [DOI: 10.1177/028418519203300604] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The findings at CT in 11 patients with primary non-Hodgkin lymphoma (NHL) of the maxillary sinus were compared with the CT findings in 21 patients with squamous cell carcinoma (SCC) of the maxillary sinus. In NHL, the segmental bone destruction was in alignment with the bony wall with a massive tumor infiltration into the neighboring structures. In contrast, all patients with SCC were characterized by a soft tissue mass with aggressive bone destruction. About half of the patients with NHL had cervical lymphadenopathy. Post-treatment recalcification of previous bone destruction was seen in 4 out of 5 NHL patients on follow-up CT. In the patients with SCC, only a few had metastatic lymphadenopathy, and no recalcification occurred after treatment. CT is therefore of importance in differentiating NHL from SCC of the maxillary sinus.
Collapse
|
29
|
Yamazaki E, Matsubara S, Yamada I. Effect of Gd-DTPA and/or Magnetic Field and Radiofrequency Exposure on Sister Chromatid Exchange in Human Peripheral Lymphocytes. Acta Radiol 2016. [DOI: 10.1177/028418519303400615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The effects of a magnetic field, radiofrequency, and gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) on the sister chromatid exchange (SCE) in human peripheral lymphocytes were investigated. Whole blood was taken from a nonsmoker and samples were exposed to magnetic force (1.5 T) alone, and to a magnetic force combined with radiofrequency waves (63.86 MHz, specific absorption rate, SAR, 0.4 W/kg). Gd-DTPA was then added to other blood samples in varying amounts and concentrations. After exposure to the conditions described above, these blood samples were cultured for 69 hours. Slides were made for an SCE evaluation. As the concentration of Gd-DTPA added to the blood increased, the SCE frequency also increased. However, the addition of Gd-DTPA at the clinical concentrations normally used did not affect the SCE frequency.
Collapse
|
30
|
Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J. The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. Leuk Lymphoma 2016; 57:2763-2770. [DOI: 10.1080/10428194.2016.1195498] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
Yamazaki E, Kanamori H, Itabashi M, Ogusa E, Numata A, Yamamoto W, Ito S, Tachibana T, Hagihara M, Matsumoto K, Koharazawa H, Taguchi J, Tomita N, Fujimaki K, Fujita H, Fujisawa S, Ogawa K, Ishigatsubo Y. Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia. Leuk Lymphoma 2016; 58:104-109. [PMID: 27267543 DOI: 10.1080/10428194.2016.1190969] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
We verified the association between standard clinical and laboratory variables and the risk of relapse in acute myeloid leukemia (AML), which led us to retrospectively examine the effect of regeneration of hematopoiesis in patients with newly diagnosed AML. We used data from 230 patients who obtained remission after cytarabine-based induction chemotherapy. Platelet counts ≥500 × 109/L and hemoglobin levels ≥9 g/dL on day 28 after treatment initiation were significantly associated with relapse-free survival (RFS) rate, conferring respective multivariate risk ratios of 0.38 (95% CI: 0.18-0.79) and 0.60 (95% CI: 0.40-0.89) for the occurrence of relapse or death. No disease relapse occurred in core binding factor leukemia patients whose platelet counts recovered ≥500 × 109/L at 28 days after therapy initiation. We conclude that regeneration of hematopoiesis, especially platelet hyper-recovery, after induction chemotherapy is a significant predictor of RFS in patients with AML.
Collapse
Affiliation(s)
- Etsuko Yamazaki
- a Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama, Japan
| | - Heiwa Kanamori
- b Department of Hematology , Kanagawa Cancer Center , Yokohama , Japan
| | - Megumi Itabashi
- c Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan
| | - Eriko Ogusa
- b Department of Hematology , Kanagawa Cancer Center , Yokohama , Japan
| | - Ayumi Numata
- c Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan
| | - Wataru Yamamoto
- b Department of Hematology , Kanagawa Cancer Center , Yokohama , Japan
| | - Satomi Ito
- d Department of Hematology , Shizuoka Red Cross Hospital , Shizuoka , Japan
| | - Takayoshi Tachibana
- a Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama, Japan
| | - Maki Hagihara
- c Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan
| | - Kenji Matsumoto
- b Department of Hematology , Kanagawa Cancer Center , Yokohama , Japan
| | - Hideyuki Koharazawa
- e Department of Hematology/Oncology , Yamato Municipal Hospital , Yamato , Japan
| | - Jun Taguchi
- d Department of Hematology , Shizuoka Red Cross Hospital , Shizuoka , Japan
| | - Naoto Tomita
- a Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama, Japan
| | - Katsumichi Fujimaki
- f Department of Hematology/Immunology , Fujisawa City Hospital , Fujisawa , Japan
| | - Hiroyuki Fujita
- g Department of Hematology , Saiseikai Yokohama Nanbu Hospital , Yokohama , Japan
| | - Shin Fujisawa
- c Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan
| | - Koji Ogawa
- h Department of Hematology , Yokosuka City Hospital , Yokosuka , Japan
| | - Yoshiaki Ishigatsubo
- a Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama, Japan
| |
Collapse
|
32
|
Miyazaki T, Abe N, Yamazaki E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Tachibana T, Kamijo A, Tomita N, Ishigastubo Y. [Successful induction therapy for acute myeloid leukemia complicated with brain hemorrhage and hyperleukocytosis]. Rinsho Ketsueki 2016; 57:180-185. [PMID: 26935637 DOI: 10.11406/rinketsu.57.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Adequate management of hyperleukocytosis in patients with acute myeloid leukemia (AML) is essential for the prevention of life-threatening complications related to leukostasis and tumor lysis syndrome, but the optimal therapeutic strategy remains unclear. We report a 15-year-old girl with newly diagnosed AML who had extreme hyperleukocytosis (leukocyte count at diagnosis, 733,000/μl) leading to a brain hemorrhage. She was initially treated with hydroxyurea, but presented with brain hemorrhage due to leukostasis and underwent leukapheresis emergently with intensive care and mechanical ventilation. Full-dose standard induction chemotherapy was initiated after achieving gradual cytoreduction (leukocyte count, 465,000/μl) within five days after the initiation of therapy with hydroxyurea and leukapheresis. These treatments were successful and she experienced no complications. The patient ultimately recovered fully and was discharged with complete remission of AML. Although the effects of hydroxyurea and leukapheresis in the setting of hyperleukocytosis are still controversial, these initial treatments may contribute to successful bridging therapy followed by subsequent induction chemotherapy, especially in AML cases with extreme hyperleukocytosis or life-threatening leukostasis.
Collapse
Affiliation(s)
- Takuya Miyazaki
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Miyashita K, Tomita N, Taguri M, Suzuki T, Ishiyama Y, Ishii Y, Nakajima Y, Numata A, Hattori Y, Yamamoto W, Miyazaki T, Tachibana T, Takasaki H, Matsumoto K, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y. Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. Leuk Res 2015; 39:S0145-2126(15)30368-4. [PMID: 26350140 DOI: 10.1016/j.leukres.2015.08.016] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2015] [Revised: 08/22/2015] [Accepted: 08/25/2015] [Indexed: 11/19/2022]
Abstract
Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy between 2003 and 2012. We assessed the prognostic significance of six biomarkers [lactate dehydrogenase, soluble interleukin-2 receptor, thymidine kinase activity, beta-2 microglobulin (B2M), C-reactive protein, and ferritin] and representative clinical characteristics using progression-free survival (PFS) as the endpoint. The study group included 181 men and 138 women with a median age of 63 years (range, 22-89 years). In a multivariate analysis, the serum B2M level most strongly correlated with PFS (hazard ratio, 2.11; P=0.04). In a univariate analysis, patients with serum B2M levels >1.75μg/mL (n=210) had a worse 3-year PFS rate (71.2%) than those with B2M levels <1.75μg/mL (n=109; 90.0%). Therefore, serum B2M level at the time of diagnosis is a useful prognostic indicator in DLBCL patients receiving R-CHOP.
Collapse
Affiliation(s)
- Kazuho Miyashita
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - Naoto Tomita
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
| | - Masataka Taguri
- Department of Biostatistics and Epidemiology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - Taisei Suzuki
- Department of Hematology, Yokosuka City Hospital, 1-3-2 Nagasaka, Yokosuka 240-0195, Japan
| | - Yasufumi Ishiyama
- Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan
| | - Yoshimi Ishii
- Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama 232-0024, Japan
| | - Yuki Nakajima
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - Ayumi Numata
- Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama 232-0024, Japan
| | - Yukako Hattori
- Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan
| | - Wataru Yamamoto
- Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama 232-0024, Japan
| | - Takuya Miyazaki
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - Takayoshi Tachibana
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - Hirotaka Takasaki
- Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan
| | - Kenji Matsumoto
- Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama 232-0024, Japan
| | - Chizuko Hashimoto
- Department of Hematology/Oncology, Yamato Municipal Hospital, 8-3-6 Fukaminishi, Yamato 242-8602, Japan
| | - Sachiya Takemura
- Department of Internal Medicine, Yokohama Ekisaikai Hospital, 1-2 Yamada-cho, Naka-ku, Yokohama 231-0036, Japan
| | - Etsuko Yamazaki
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| | - Katsumichi Fujimaki
- Department of Hematology/Immunology, Fujisawa City Hospital, 2-6-1 Fujisawa, Fujisawa 251-8550, Japan
| | - Rika Sakai
- Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan
| | - Shigeki Motomura
- Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan
| | - Yoshiaki Ishigatsubo
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
| |
Collapse
|
34
|
Tomita N, Taguri M, Hashimoto C, Takasaki H, Fujimaki K, Motomura S, Koharazawa H, Takemura S, Fujita H, Yamazaki E, Kawasaki R, Taguchi J, Sakai R, Fujisawa S, Hattori Y, Kanamori H, Yamamoto W, Harano H, Ogawa K, Ishigatsubo Y. Evaluation of soluble interleukin-2 receptor and serum lactate dehydrogenase in malignant lymphoma. Ann Hematol 2015. [PMID: 26208667 DOI: 10.1007/s00277-015-2448-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Naoto Tomita
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
| | - Masataka Taguri
- Department of Biostatistics and Epidemiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Chizuko Hashimoto
- Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan
| | - Hirotaka Takasaki
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Katsumichi Fujimaki
- Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan
| | - Shigeki Motomura
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | | | - Sachiya Takemura
- Department of Internal Medicine, Yokohama Ekisaikai Hospital, Yokohama, Japan
| | - Hiroyuki Fujita
- Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan
| | - Etsuko Yamazaki
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
| | - Rika Kawasaki
- Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan
| | - Jun Taguchi
- Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan
| | - Rika Sakai
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Shin Fujisawa
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - Yukako Hattori
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Heiwa Kanamori
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Wataru Yamamoto
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - Hiroshi Harano
- Department of Hematology, Yokosuka City Hospital, Yokosuka, Japan
| | - Koji Ogawa
- Department of Hematology, Yokosuka City Hospital, Yokosuka, Japan
| | - Yoshiaki Ishigatsubo
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
| |
Collapse
|
35
|
Tachibana T, Tanaka M, Hagihara M, Kawasaki R, Yamazaki E, Koharazawa H, Taguchi J, Tomita N, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H. Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia. Int J Hematol 2015; 102:451-9. [PMID: 26173594 DOI: 10.1007/s12185-015-1836-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Revised: 06/30/2015] [Accepted: 07/07/2015] [Indexed: 11/26/2022]
Abstract
A multicenter retrospective study was performed to determine the significance of adding cytarabine (CA) or thiotepa (TT) in the context of total body irradiation (TBI) and cyclophosphamide (CY). A total of 322 patients who underwent allogeneic hematopoietic cell transplantation (HCT) were distributed to the following three groups: TBI/CY (n = 75), TBI/CY/CA (n = 77), and TBI/CY/TT (n = 170). In the TBI/CY/TT group, 164 of patients (96 %) received HCT during the previous year (2000-2005). Multivariate analysis revealed that the TBI/CY/TT group demonstrated a trend of poorer survival rate than the TBI/CY group, [hazard ratio (HR) = 1.49, 95 % confidence interval (CI) 0.99-2.24, P = 0.055] with a higher non-relapse mortality (NRM) (HR = 2.34, 95 % CI 1.35-4.06, P = 0.002) rates, while TBI/CY/CA group demonstrated similar outcomes. Even in the subgroup analyses of disease type or disease risk, the outcomes with intensified conditioning regimens were not superior to those with TBI/CY. In conclusion, although the significant bias has to be carefully considered, the clinical benefit of adding CA or TT to the TBI/CY regimen was not demonstrated.
Collapse
Affiliation(s)
- Takayoshi Tachibana
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
| | - Masatsugu Tanaka
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Maki Hagihara
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Rika Kawasaki
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - Etsuko Yamazaki
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
| | | | - Jun Taguchi
- Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan
| | - Naoto Tomita
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
| | | | - Rika Sakai
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - Hiroyuki Fujita
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
| | - Shin Fujisawa
- Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
| | - Atsuo Maruta
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| | - Yoshiaki Ishigatsubo
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
| | - Heiwa Kanamori
- Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
| |
Collapse
|
36
|
Koharazawa H, Watanabe R, Hattori Y, Numata A, Kawasaki R, Kuwabara H, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Taguchi J, Tomita N, Fujita H, Sakai R, Harano H, Ishigatsubo Y, Fujisawa S. [Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy]. Rinsho Ketsueki 2015; 56:392-9. [PMID: 25971269 DOI: 10.11406/rinketsu.56.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We retrospectively analyzed, and herein discuss, the outcomes of and prognostic factors for 35 untreated multiple myeloma patients less than 65 years of age who received induction therapies with bortezomib (Bor) and dexamethasone (BD) for the purpose of up-front autologous peripheral blood stem cell transplantation (SCT). The overall response rate was 77% (27 cases, including 4 [11%] complete response and 13 [37%] very good partial response cases). The rate of SCT accomplishment was 51% (18 cases). The 3 year-progression free survival (PFS) rate for the SCT group was significantly higher than that of the non-SCT group (41% vs 0%, P=0.0037). This result reflects the significantly more severe adverse effects of induction therapy for the non-SCT than the SCT group. Among reasons for SCT drop-out, 29% of cases suffered severe peripheral neuropathy with features such as irreversible numbness and pain. The analysis of PFS revealed a cytogenetic factor, favorable chromosomal type at diagnosis, to predict a better outcome (P values on univariate and multivariate analyses were 0.0004 and 0.0405, respectively). Our observations suggest establishment of induction therapy, aimed at reducing adverse effects and overcoming unfavorable cytogenetic abnormalities, to be necessary for improving the outcomes of patients with multiple myeloma.
Collapse
|
37
|
Taniyasu S, Yamashita N, Yamazaki E, Rostkowski P, Yeung LWY, Kurunthachalam SK, Kannan K, Loganathan BG. Contamination Profiles of Perfluorinated Chemicals in the Inland and Coastal Waters of Japan Following the Use of Fire-Fighting Foams. ACS Symposium Series 2015. [DOI: 10.1021/bk-2015-1206.ch011] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- S. Taniyasu
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan
- University of Sussex, School of Life Sciences, Department of Biology and Environmental Science, BN1 9QG Brighton, United Kingdom
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada
- Department of Research and Consultancy, Avinashilingam University, Coimbatore 641043, Tamil Nadu, India
- Wadsworth Center, New York State Department of Health and Department of Environmental Toxicology and Health, State University of New York, Empire State Plaza, PO Box 509, Albany, New York 12202-0509, U.S.A
| | - N. Yamashita
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan
- University of Sussex, School of Life Sciences, Department of Biology and Environmental Science, BN1 9QG Brighton, United Kingdom
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada
- Department of Research and Consultancy, Avinashilingam University, Coimbatore 641043, Tamil Nadu, India
- Wadsworth Center, New York State Department of Health and Department of Environmental Toxicology and Health, State University of New York, Empire State Plaza, PO Box 509, Albany, New York 12202-0509, U.S.A
| | - E. Yamazaki
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan
- University of Sussex, School of Life Sciences, Department of Biology and Environmental Science, BN1 9QG Brighton, United Kingdom
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada
- Department of Research and Consultancy, Avinashilingam University, Coimbatore 641043, Tamil Nadu, India
- Wadsworth Center, New York State Department of Health and Department of Environmental Toxicology and Health, State University of New York, Empire State Plaza, PO Box 509, Albany, New York 12202-0509, U.S.A
| | - P. Rostkowski
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan
- University of Sussex, School of Life Sciences, Department of Biology and Environmental Science, BN1 9QG Brighton, United Kingdom
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada
- Department of Research and Consultancy, Avinashilingam University, Coimbatore 641043, Tamil Nadu, India
- Wadsworth Center, New York State Department of Health and Department of Environmental Toxicology and Health, State University of New York, Empire State Plaza, PO Box 509, Albany, New York 12202-0509, U.S.A
| | - L. W. Y. Yeung
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan
- University of Sussex, School of Life Sciences, Department of Biology and Environmental Science, BN1 9QG Brighton, United Kingdom
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada
- Department of Research and Consultancy, Avinashilingam University, Coimbatore 641043, Tamil Nadu, India
- Wadsworth Center, New York State Department of Health and Department of Environmental Toxicology and Health, State University of New York, Empire State Plaza, PO Box 509, Albany, New York 12202-0509, U.S.A
| | - S. K. Kurunthachalam
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan
- University of Sussex, School of Life Sciences, Department of Biology and Environmental Science, BN1 9QG Brighton, United Kingdom
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada
- Department of Research and Consultancy, Avinashilingam University, Coimbatore 641043, Tamil Nadu, India
- Wadsworth Center, New York State Department of Health and Department of Environmental Toxicology and Health, State University of New York, Empire State Plaza, PO Box 509, Albany, New York 12202-0509, U.S.A
| | - K. Kannan
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan
- University of Sussex, School of Life Sciences, Department of Biology and Environmental Science, BN1 9QG Brighton, United Kingdom
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada
- Department of Research and Consultancy, Avinashilingam University, Coimbatore 641043, Tamil Nadu, India
- Wadsworth Center, New York State Department of Health and Department of Environmental Toxicology and Health, State University of New York, Empire State Plaza, PO Box 509, Albany, New York 12202-0509, U.S.A
| | - B. G. Loganathan
- National Institute of Advanced Industrial Science and Technology (AIST), 16-1 Onogawa, Tsukuba, Ibaraki 305-8569, Japan
- University of Sussex, School of Life Sciences, Department of Biology and Environmental Science, BN1 9QG Brighton, United Kingdom
- Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada
- Department of Research and Consultancy, Avinashilingam University, Coimbatore 641043, Tamil Nadu, India
- Wadsworth Center, New York State Department of Health and Department of Environmental Toxicology and Health, State University of New York, Empire State Plaza, PO Box 509, Albany, New York 12202-0509, U.S.A
| |
Collapse
|
38
|
Nakajima Y, Tomita N, Itabashi M, Miyashita K, Watanabe R, Miyazaki T, Tachibana T, Takasaki H, Kawasaki R, Tanaka M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Harano H, Motomura S, Ishigatsubo Y. Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy. Leuk Res 2014; 39:198-203. [PMID: 25541027 DOI: 10.1016/j.leukres.2014.11.030] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Revised: 11/24/2014] [Accepted: 11/29/2014] [Indexed: 10/24/2022]
Abstract
The prognostic implications of infra-diaphragmatic (InD) versus supra-diaphragmatic (SpD) primary lesions in limited-stage diffuse large B-cell lymphoma (DLBCL) remains unknown. This retrospective study aimed to assess the prognostic impact of spD and InD lesions as well as presence of gastrointestinal (GI) involvements in adults with limited-stage DLBCL. We analyzed data from 178 patients with limited-stage DLBCL who were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy at 7 institutions of the Yokohama City University Hematology Group between 2003 and 2009. The median age was 63 years (range, 18-80 years). The primary sites were SpD in 109 patients, and InD in 69. No statistical differences in progression-free survival (PFS) or overall survival (OS) were observed between patients with SpD lesions and those with InD lesions. However, when patients with SpD lesions, InD lesions with (n=35), and without (n=34) GI involvement were compared, the presence of GI lesions was associated with favorable PFS. The multivariate analysis revealed that SpD or InD localization had no independent effect on PFS or OS, whereas the presence of GI lesions was correlated with favorable PFS (P=0.024, HR 0.09).
Collapse
Affiliation(s)
- Yuki Nakajima
- Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
| | - Naoto Tomita
- Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Megumi Itabashi
- Department of Hematology, Yokohama City University, Medical Center, Yokohama, Japan
| | - Kazuho Miyashita
- Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan
| | - Reina Watanabe
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Takuya Miyazaki
- Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Takayoshi Tachibana
- Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Hirotaka Takasaki
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Rika Kawasaki
- Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan
| | - Masatsugu Tanaka
- Department of Hematology, Yokohama City University, Medical Center, Yokohama, Japan
| | - Chizuko Hashimoto
- Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan
| | - Etsuko Yamazaki
- Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| | - Jun Taguchi
- Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan
| | - Katsumichi Fujimaki
- Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan
| | - Rika Sakai
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Hiroyuki Fujita
- Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan
| | - Shin Fujisawa
- Department of Hematology, Yokohama City University, Medical Center, Yokohama, Japan
| | - Hiroshi Harano
- Department of Hematology, Yokosuka City Hospital, Yokosuka, Japan
| | - Shigeki Motomura
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Yoshiaki Ishigatsubo
- Department of Internal Medicine and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
39
|
Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y, Emi N, Tamaki S, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K, Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T. Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial. J Clin Oncol 2014; 32:3729-35. [DOI: 10.1200/jco.2013.53.3570] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose The introduction of all-trans-retinoic acid (ATRA) has significantly improved outcomes for acute promyelocytic leukemia (APL), although a subset of patients still suffer relapse. The purpose of this study was to evaluate the role of maintenance therapy with the synthetic retinoid tamibarotene in APL. Patients and Methods Patients with newly diagnosed APL in molecular remission at the end of consolidation therapy were randomly assigned to receive ATRA or tamibarotene, both orally, for 14 days every 3 months for up to 2 years. Results A total of 347 patients were enrolled. Of the 344 eligible patients, 319 (93%) achieved complete remission. After completing three courses of consolidation therapy, 269 patients underwent maintenance random assignment. The relapse-free survival (RFS) rate at 4 years was 84% for the ATRA arm and 91% for the tamibarotene arm (hazard ratio [HR], 0.54; 95% CI, 0.26 to 1.13). When the analysis was restricted to 52 high-risk patients with an initial WBC count ≥ 10.0 × 109/L, the intergroup difference was statistically significant, with 4-year RFS rates of 58% for the ATRA arm and 87% for the tamibarotene arm (HR, 0.26; 95% CI, 0.07 to 0.95). For patients with non–high-risk disease, the HR was 0.82 (95% CI, 0.32 to 2.01). The test for interaction between treatment effects and these subgroups resulted in P = .075. Both treatments were generally well tolerated. Conclusion In this trial, no difference was detected between ATRA and tamibarotene for maintenance therapy. In an exploratory analysis, there was a suggestion of improved efficacy of tamibarotene in high-risk patients, but this requires further study.
Collapse
Affiliation(s)
- Katsuji Shinagawa
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Masamitsu Yanada
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Toru Sakura
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Yasunori Ueda
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Masashi Sawa
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Junichi Miyatake
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Nobuaki Dobashi
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Minoru Kojima
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Yoshihiro Hatta
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Nobuhiko Emi
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Shigehisa Tamaki
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Hiroshi Gomyo
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Etsuko Yamazaki
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Katsumichi Fujimaki
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Norio Asou
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Keitaro Matsuo
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Shigeki Ohtake
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Yasushi Miyazaki
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Kazunori Ohnishi
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Yukio Kobayashi
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| | - Tomoki Naoe
- Katsuji Shinagawa, Okayama University Hospital, Okayama; Masamitsu Yanada and Nobuhiko Emi, Fujita Health University School of Medicine, Toyoake; Toru Sakura, Saiseikai Maebashi Hospital, Maebashi; Yasunori Ueda, Kurashiki Central Hospital, Kurashiki; Masashi Sawa, Anjo Kosei Hospital, Anjo; Junichi Miyatake, Kinki University Faculty of Medicine, Osakasayama; Nobuaki Dobashi, Jikei University School of Medicine; Yoshihiro Hatta, Nihon University School of Medicine; Yukio Kobayashi, National Cancer Center
| |
Collapse
|
40
|
Yamazaki E, Tomita N, Koyama S, Ogusa E, Ishii Y, Takahashi H, Miyashita K, Matsuura S, Tachibana T, Takasaki H, Takemura S, Fujimaki K, Sakai R, Fujisawa S, Ishigatsubo Y. Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type. Med Oncol 2014; 31:149. [PMID: 25108598 DOI: 10.1007/s12032-014-0149-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Accepted: 07/26/2014] [Indexed: 11/26/2022]
Abstract
The objective of the current study was to assess the prognostic factors in patients with extranodal natural killer (NK)/T cell lymphoma, nasal type (ENKL). We retrospectively analyzed 35 patients who were diagnosed with ENKL between 1998 and 2011. The median patient age was 63 years, and the male/female ratio was 22:13; twenty patients had localized ENKL, and 26 had a good Eastern Cooperative Oncology Group performance status (score 0 or 1). B symptoms were present in 17 patients. Twenty-five patients presented with nasal or paranasal lesions, or both. With a median follow-up duration among patients still alive at their last follow-up of 47 months (range 8-93 months), the 3-year overall survival (OS) rate was 44.5 %. Multivariate analysis revealed that advanced disease stage (P = 0.002), the presence of extranasal disease (P = 0.013), and serum ferritin levels greater than 300 ng/ml (P < 0.001) were significant and independent (negative) prognostic factors. High serum ferritin levels were associated with the presence of B symptoms, elevated lactate dehydrogenase levels, and high soluble interleukin-2 receptor levels, but not with clinical stage. Patients with high ferritin levels had a remarkably low remission rate (23 %) and a short OS time (median: 4 months). Serum ferritin level at the time of diagnosis of ENKL was a useful prognostic factor.
Collapse
Affiliation(s)
- Etsuko Yamazaki
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, 2360004, Japan,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Yamamoto E, Yamazaki E, Ishiyama Y, Koyama S, Ishii Y, Hattori Y, Nakajima Y, Tachibana T, Miyazaki T, Hagihara M, Tomita N, Ishigatsubo Y. [T315I positive promyelocytic crisis of chronic myeloid leukemia]. Rinsho Ketsueki 2014; 55:692-696. [PMID: 24975339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Promyelocytic crisis (PMC) of chronic myelogenous leukemia (CML) is relatively rare. We report a patient who progressed to PMC with a T315I mutation during the initial treatment with dasatinib for CML. He obtained hematological remission after combination therapy with all-trans retinoic acid and chemotherapy for PMC, and PML-RARA was not detected by FISH analysis. Arsenic trioxide (ATO) and imatinib therapy induced a second complete cytogenetic response, and PML-RARA mRNA detected by real-time quantitative RT-PCR dropped below the detection limit. Finally, allogeneic stem cell transplantation was performed. This case suggests that combination therapy with imatinib and ATO achieves favorable outcomes for PMC.
Collapse
MESH Headings
- Adult
- Allografts
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Bone Marrow Transplantation
- Disease Progression
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/therapy
- Male
- Mutation
- Remission Induction
Collapse
Affiliation(s)
- Eri Yamamoto
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Umegaki T, Sakamoto S, Nishi K, Okamoto A, Onose A, Hamano N, Yamazaki E, Shingu K. Impact of steroid medication before hospital admission on barotrauma in mechanically ventilated patients with acute respiratory distress syndrome in intensive care units. J Anesth 2014; 28:681-6. [PMID: 24554247 DOI: 10.1007/s00540-014-1799-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Accepted: 01/26/2014] [Indexed: 10/25/2022]
Abstract
PURPOSE To investigate the association between steroid medication before hospital admission and barotrauma in mechanically ventilated patients with acute respiratory distress syndrome (ARDS). METHODS An observational single-center retrospective study was conducted using patients admitted to the general intensive care unit (ICU) of a university hospital in Japan. We analyzed 149 mechanically ventilated patients with ARDS hospitalized between March 2008 and March 2011. ARDS was identified according to criteria from the Berlin Definition. Barotrauma was defined as pneumothorax, subcutaneous emphysema, or mediastinal emphysema occurring during mechanical ventilation in the ICU. The influence of steroid medication before hospital admission on barotrauma was studied using multiple logistic regression analysis. RESULTS There were no differences in baseline patient characteristics except for congestive heart failure, peak pressure during mechanical ventilation, and steroid pulse therapy between the barotrauma and non-barotrauma groups. Logistic regression analysis showed that peak pressure ≥35 cmH2O was associated with barotrauma in patients with ARDS [odds ratio (OR), 17.34; P < 0.01], whereas steroid medication before hospital admission was not a significant factor for barotrauma (OR, 1.63; P = 0.51). CONCLUSIONS Barotrauma in ARDS patients was associated with higher pressure during mechanical ventilation but not with steroid medication before hospital admission.
Collapse
Affiliation(s)
- Takeshi Umegaki
- Department of General Intensive Care Unit, Hirakata Hospital, Kansai Medical University, 2-3-1 Shin-machi, Hirakata, Osaka, 573-1191, Japan,
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Tomita N, Kodama F, Tsuyama N, Sakata S, Takeuchi K, Ishibashi D, Koyama S, Ishii Y, Yamamoto W, Takasaki H, Hagihara M, Kuwabara H, Tanaka M, Hashimoto C, Yamazaki E, Koharazawa H, Fujimaki K, Sakai R, Fujisawa S, Ishigatsubo Y. Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients. Hematol Oncol 2014; 33:9-14. [DOI: 10.1002/hon.2136] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2013] [Revised: 01/04/2014] [Accepted: 01/07/2014] [Indexed: 11/06/2022]
Affiliation(s)
- Naoto Tomita
- Department of Internal Medicine and Clinical Immunology; Yokohama City University Graduate School of Medicine; Yokohama Japan
| | - Fumio Kodama
- Department of Medical Oncology; Kanagawa Cancer Center; Yokohama Japan
| | - Naoko Tsuyama
- Division of Pathology, The Cancer Institute; Japanese Foundation for Cancer Research; Tokyo Japan
| | - Seiji Sakata
- Pathology Project for Molecular Targets, The Cancer Institute; Japanese Foundation for Cancer Research; Tokyo Japan
| | - Kengo Takeuchi
- Division of Pathology, The Cancer Institute; Japanese Foundation for Cancer Research; Tokyo Japan
- Pathology Project for Molecular Targets, The Cancer Institute; Japanese Foundation for Cancer Research; Tokyo Japan
| | | | - Satoshi Koyama
- Department of Hematology; Shizuoka Red Cross Hospital; Shizuoka Japan
| | - Yoshimi Ishii
- Department of Internal Medicine and Clinical Immunology; Yokohama City University Graduate School of Medicine; Yokohama Japan
| | - Wataru Yamamoto
- Department of Medical Oncology; Kanagawa Cancer Center; Yokohama Japan
| | - Hirotaka Takasaki
- Department of Medical Oncology; Kanagawa Cancer Center; Yokohama Japan
| | - Maki Hagihara
- Department of Internal Medicine and Clinical Immunology; Yokohama City University Graduate School of Medicine; Yokohama Japan
| | - Hideyuki Kuwabara
- Department of Hematology; Yokohama City University Medical Center; Yokohama Japan
| | - Masatsugu Tanaka
- Department of Hematology; Yokohama City University Medical Center; Yokohama Japan
| | - Chizuko Hashimoto
- Department of Medical Oncology; Kanagawa Cancer Center; Yokohama Japan
| | - Etsuko Yamazaki
- Department of Internal Medicine and Clinical Immunology; Yokohama City University Graduate School of Medicine; Yokohama Japan
| | | | | | - Rika Sakai
- Department of Medical Oncology; Kanagawa Cancer Center; Yokohama Japan
| | - Shin Fujisawa
- Department of Hematology; Yokohama City University Medical Center; Yokohama Japan
| | - Yoshiaki Ishigatsubo
- Department of Internal Medicine and Clinical Immunology; Yokohama City University Graduate School of Medicine; Yokohama Japan
| |
Collapse
|
44
|
Ishii Y, Tomita N, Tateishi U, Ishiyama Y, Yamamoto E, Hattori Y, Hagihara M, Yamazaki E, Ishigatsubo Y. The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients. Med Oncol 2014; 31:880. [PMID: 24504845 DOI: 10.1007/s12032-014-0880-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Accepted: 01/30/2014] [Indexed: 11/26/2022]
Abstract
[18F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is useful for primary staging and evaluation of treatment outcome in diffuse large B cell lymphoma (DLBCL) patients. The reduction in the maximum standardized uptake value (ΔSUVmax) from the initial to the interim 18F-FDG PET scan has been reported to predict survival in DLBCL patients. We retrospectively evaluated ΔSUVmax obtained by PET or PET-computed tomography before and after initial therapy in 31 newly diagnosed DLBCL patients who were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy. Receiver observation characteristic curve analysis was used to evaluate the optimal cutoff value for the ΔSUVmax for disease progression. The 3-year progression-free survival rate of patients with ΔSUVmax≥83 and <83% was found to be 91 and 25%, respectively (P<0.001). The 4-year overall survival rate of patients with ΔSUVmax≥83 and <83% was found to be 100 and 83%, respectively (P=0.046). The ΔSUVmax observed before and after R-CHOP therapy could be useful in the prediction of disease progression and survival in newly diagnosed DLBCL patients.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cyclophosphamide/administration & dosage
- Disease Progression
- Doxorubicin/administration & dosage
- Female
- Fluorodeoxyglucose F18
- Follow-Up Studies
- Humans
- Lymphoma, Large B-Cell, Diffuse/diagnostic imaging
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Middle Aged
- Neoplasm Staging
- Positron-Emission Tomography/methods
- Prednisolone/administration & dosage
- Prognosis
- Radiopharmaceuticals
- Retrospective Studies
- Rituximab
- Survival Rate
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- Yoshimi Ishii
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama, 236-0004, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, Hashimoto C, Itabashi M, Ishibashi D, Nakajima Y, Tachibana T, Kawasaki R, Kuwabara H, Koharazawa H, Yamazaki E, Tomita N, Sakai R, Fujita H, Kanamori H, Ishigatsubo Y. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci 2014; 105:105-9. [PMID: 24450386 PMCID: PMC4317875 DOI: 10.1111/cas.12321] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2013] [Revised: 10/25/2013] [Accepted: 11/05/2013] [Indexed: 01/28/2023] Open
Abstract
The Sokal and Hasford scores were developed in the chemotherapy and interferon era and are widely used as prognostic indicators in patients with chronic myeloid leukemia (CML). Recently, a new European Treatment and Outcome Study (EUTOS) scoring system was developed. We performed a multicenter retrospective study to validate the effectiveness of each of the three scoring systems. The study cohort included 145 patients diagnosed with CML in chronic phase who were treated with imatinib. In the EUTOS low- and high-risk groups, the cumulative incidence of complete cytogenetic response (CCyR) at 18 months was 86.9% and 87.5% (P = 0.797) and the 5-year overall survival rate was 92.6% and 93.3% (P = 0.871), respectively. The cumulative incidence of CCyR at 12 months, 5-year event-free survival and 5-year progression-free survival were not predicted using the EUTOS scoring system. However, there were significant differences in both the Sokal score and Hasford score risk groups. In our retrospective validation study, the EUTOS score did not predict the prognosis of patients with CML in chronic phase treated with imatinib.
Collapse
Affiliation(s)
- Eri Yamamoto
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol 2013; 92:204-10. [PMID: 24283206 DOI: 10.1111/ejh.12221] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/21/2013] [Indexed: 12/13/2022]
Abstract
OBJECTIVES The tumor microenvironment, including tumor-infiltrating lymphocytes and myeloid-derived cells, is an important factor in the pathogenesis and clinical behavior of malignant lymphoma. However, the prognostic significance of peripheral lymphocytes and monocytes in lymphoma remains unclear. METHODS We evaluated the prognostic impact of the absolute lymphocyte count (ALC), absolute monocyte count (AMC), and lymphocyte/monocyte ratio (LMR) in 359 diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). RESULTS The median follow-up time of the surviving patients was 58 months. Low ALC and an elevated AMC were both associated with poor survival rates. Receiver operating characteristic curve analysis showed that LMR was the best predictor of survival, with 4.0 as the cutoff point. Patients with LMR ≤4.0 were more likely to have an aggressive tumor, and this was associated with poor treatment responses. Patients with LMR ≤4.0 at diagnosis had significantly poorer overall survival (OS) and progression-free survival (PFS) than those with LMR >4.0. Multivariate analysis, which included prognostic factors of the International Prognostic Index, showed LMR ≤4.0 to be an independent predictor for the OS (hazard ratio [HR], 2.507; 95% confidence interval [CI], 1.255-5.007; P = 0.009) and PFS (HR, 2.063; 95% CI, 1.249-3.408; P = 0.005). CONCLUSIONS The LMR at diagnosis, as a simple index which reflects host systemic immunity, predicts clinical outcomes in DLBCL patients treated with R-CHOP.
Collapse
Affiliation(s)
- Reina Watanabe
- Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan; Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Ishii Y, Yamazaki E, Ishiyama Y, Yamamoto E, Hattori Y, Hagihara M, Tomita N, Ishigatsubo Y. Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation. Int J Hematol 2013; 98:723-8. [PMID: 24166587 DOI: 10.1007/s12185-013-1456-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Revised: 10/04/2013] [Accepted: 10/16/2013] [Indexed: 01/18/2023]
Abstract
POEMS syndrome is a monoclonal plasma cell disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) are an effective therapy, but optimal treatment options are still under debate. Bortezomib is an important agent for the treatment of patients with multiple myeloma and has recently been reported as efficacious in the treatment of patients with POEMS syndrome. We present a case of POEMS syndrome in a 33-year-old woman, who was successfully treated with BorDex (bortezomib and dexamethasone) combined with radiotherapy, and followed by ASCT. She was diagnosed with POEMS syndrome with a localized plasmacytoma of bone 5 months after her initial symptoms of heart failure. Her Eastern Cooperative Oncology Group (ECOG) performance status was 4. She was first administered BorDex therapy, which was subsequently combined with radiotherapy. Her general condition including heart failure dramatically improved after four cycles of BorDex therapy and radiation, resulting in partial response. After chemoradiotherapy, HDT and ASCT were performed. After treatment, she was able to walk unassisted and her plasma endothelial growth factor (VEGF) level decreased. She did not experience neurotoxicity induced by bortezomib. Bortezomib was well tolerated and we suggest that BorDex therapy followed by HDT and ASCT may be an effective therapy for POEMS syndrome.
Collapse
Affiliation(s)
- Yoshimi Ishii
- Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama, 236-0004, Japan,
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Takahashi Y, Imai K, Ikeda H, Kubota Y, Yamazaki E, Susa F. Open study of pranlukast add-on therapy in intractable partial epilepsy. Brain Dev 2013; 35:236-44. [PMID: 22571867 DOI: 10.1016/j.braindev.2012.04.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2012] [Revised: 04/09/2012] [Accepted: 04/13/2012] [Indexed: 01/17/2023]
Abstract
Innovative treatments of epileptic seizures are needed to improve the outcome of epilepsy. We studied the effect of pranlukast on seizure outcome in patients with intractable partial epilepsy. An open study was conducted to evaluate the clinical efficacy of 24-week pranlukast add-on therapy in 50 patients with intractable partial seizures. Serum concentrations of matrix metalloproteinase (MMP)-9 were determined using Biotrak Activity Assay System. Cytokines in cerebrospinal fluid (CSF) were measured by the BioPlex (BioRad) system and soluble TNF receptor1 (sTNFR1) in CSF was measured by the ELISA. Surface markers of lymphocytes in CSF were examined by cell-sorter. Seizure-free rate (SFR) was 13.6%, responder rate (RR) was 47.7%, and aggravation rate (AR) was 18.2% at the 13-24 week period after starting pranlukast. In patients with increased serum MMP-9 before pranlukast therapy (baseline), comparison of paired serum levels showed a significant decrease after pranlukast therapy. Baseline CSF levels of IL-1β and IL-6 were elevated in patients compared with disease controls. Of four patients with paired data, three (including a responder to pranlukast) showed decreased pro-inflammatory cytokines (IL-1β, IL-6, and TNFα), and four showed decreased sTNFR1, after pranlukast treatment, and only a responder had markedly decreased frequency of CD8+ T cells in CSF. Pranlukast reduces seizure frequencies probably by pleiotropic effects including normalization of MMP-9 in sera, reduced leakage of pro-inflammatory cytokines into CNS, and inhibition of extravasation of leucocytes from brain capillaries. Further investigations by double-blind control study and animal models are warranted.
Collapse
Affiliation(s)
- Yukitoshi Takahashi
- National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Aoi-ku, Shizuoka 420-8688, Japan.
| | | | | | | | | | | |
Collapse
|
49
|
Tomita N, Takasaki H, Miyashita K, Fujisawa S, Ogusa E, Matsuura S, Kishimoto K, Numata A, Fujita A, Ohshima R, Kuwabara H, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Fujimaki K, Taguchi J, Sakai R, Ishigatsubo Y. R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. Br J Haematol 2013; 161:383-8. [DOI: 10.1111/bjh.12281] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2012] [Accepted: 11/19/2012] [Indexed: 11/28/2022]
Affiliation(s)
- Naoto Tomita
- Department of Internal Medicine and Clinical Immunology; Yokohama City University Graduate School of Medicine; Yokohama; Japan
| | - Hirotaka Takasaki
- Department of Medical Oncology; Kanagawa Cancer Centre; Yokohama; Japan
| | - Kazuho Miyashita
- Department of Haematology/Immunology; Fujisawa City Hospital; Fujisawa; Japan
| | - Shin Fujisawa
- Department of Haematology; Yokohama City University Medical Centre; Yokohama; Japan
| | - Eriko Ogusa
- Department of Haematology; Shizuoka Red Cross Hospital; Shizuoka; Japan
| | - Shiro Matsuura
- Department of Haematology; Yamato City Hospital; Yamato; Japan
| | - Kumiko Kishimoto
- Department of Haematology; Yokosuka City Hospital; Yokosuka; Japan
| | - Ayumi Numata
- Department of Haematology/Immunology; Fujisawa City Hospital; Fujisawa; Japan
| | - Atsuko Fujita
- Department of Haematology; Yokohama City University Medical Centre; Yokohama; Japan
| | - Rika Ohshima
- Department of Medical Oncology; Kanagawa Cancer Centre; Yokohama; Japan
| | - Hideyuki Kuwabara
- Department of Haematology; Yokohama City University Medical Centre; Yokohama; Japan
| | - Maki Hagihara
- Department of Internal Medicine and Clinical Immunology; Yokohama City University Graduate School of Medicine; Yokohama; Japan
| | | | - Sachiya Takemura
- Department of Medical Oncology; Kanagawa Cancer Centre; Yokohama; Japan
| | - Hideyuki Koharazawa
- Department of Haematology/Immunology; Fujisawa City Hospital; Fujisawa; Japan
| | - Etsuko Yamazaki
- Department of Internal Medicine and Clinical Immunology; Yokohama City University Graduate School of Medicine; Yokohama; Japan
| | - Katsumichi Fujimaki
- Department of Haematology/Immunology; Fujisawa City Hospital; Fujisawa; Japan
| | - Jun Taguchi
- Department of Haematology; Shizuoka Red Cross Hospital; Shizuoka; Japan
| | - Rika Sakai
- Department of Medical Oncology; Kanagawa Cancer Centre; Yokohama; Japan
| | - Yoshiaki Ishigatsubo
- Department of Internal Medicine and Clinical Immunology; Yokohama City University Graduate School of Medicine; Yokohama; Japan
| |
Collapse
|
50
|
Yamamoto W, Nakamura N, Tomita N, Ishii Y, Takasaki H, Hashimoto C, Motomura S, Yamazaki E, Ohshima R, Numata A, Ishigatsubo Y, Sakai R. Clinicopathological analysis of mediastinal large B-cell lymphoma and classical Hodgkin lymphoma of the mediastinum. Leuk Lymphoma 2012; 54:967-72. [DOI: 10.3109/10428194.2012.733881] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|